Multiplexed magnetic nanoparticle-antibody conjugates (MNPs-ABS) based prognostic detection of ovarian cancer biomarkers, CA-125, β-2M and ApoA1 using fluorescence spectroscopy with comparison of surface plasmon resonance (SPR) analysis

Biosens Bioelectron. 2015 Nov 15:73:146-152. doi: 10.1016/j.bios.2015.05.051. Epub 2015 May 25.

Abstract

A multiplexed MNPs-Abs based fluorescence spectroscopic system in analysis of serum biomarkers; CA-125, β2-M and ApoA1 for the early detection of ovarian cancer was first time proposed. The lowest detection limits measured in multiplexed setup were 0.26 U/mL, 0.55 ng/mL and 7.7 ng/mL respectively for CA-125, β2-M and ApoA1. A comparative real sample analysis of healthy normal (Control), benign and ovarian cancer patients with SPR has also been done to validate the process. Moreover CA-125 detection only confirms 50-60% of early stage disease. This multiplexed system achieved sensitivity and specificity up to 94% and 98% respectively to distinguish early stage ovarian cancer patients from healthy individuals.

Keywords: Antibodies; Biosensor; Functionalized MNPs; Multiplexed; Ovarian cancer.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Immobilized
  • Apolipoprotein A-I / blood*
  • Biomarkers, Tumor / blood*
  • CA-125 Antigen / blood*
  • Case-Control Studies
  • Early Detection of Cancer / methods
  • Female
  • Humans
  • Limit of Detection
  • Magnetite Nanoparticles
  • Membrane Proteins / blood*
  • Middle Aged
  • Nanoconjugates
  • Ovarian Neoplasms / blood*
  • Ovarian Neoplasms / diagnosis
  • Prognosis
  • Spectrometry, Fluorescence / methods*
  • Surface Plasmon Resonance / methods*
  • beta 2-Microglobulin / blood*

Substances

  • APOA1 protein, human
  • Antibodies, Immobilized
  • Apolipoprotein A-I
  • Biomarkers, Tumor
  • CA-125 Antigen
  • MUC16 protein, human
  • Magnetite Nanoparticles
  • Membrane Proteins
  • Nanoconjugates
  • beta 2-Microglobulin